Back أكتافس Arabic Актавис Bulgarian Actavis German Actavis Spanish Actavis Generics Estonian اکتاویس Persian Actavis French Actavis ID Actavis Icelandic Actavis Malay
 | |
| Company type | Subsidiary |
|---|---|
| NYSE: ACT | |
| Industry | Branded and generic pharmaceuticals, and pharmaceutical research and development |
| Founded | March 1984 in Libertyville, Illinois, United States |
| Founder | Allen Chao, Ph.D. and David Hsia, Ph.D. |
| Defunct | 2015 |
| Fate | 2015 Irish tax inversion and merger with Allergan, Inc. |
| Successor | Allergan, plc |
| Headquarters | Dublin, Ireland and Parsippany-Troy Hills, New Jersey, United States |
Number of locations | 40 manufacturing facilities 27 global R&D centers |
Area served | ≈100 countries |
Key people | Brenton L. Saunders (CEO and president) Paul Bisaro (executive chairman) |
| Products | Branded and generic pharmaceuticals |
| Revenue | US$13.062 billion (2014) |
 US$1.090 billion (2014) | |
 US$−1.63 billion (2014) | |
| Total assets | US$6.881 billion (2014) |
| Total equity | US$28.335 billion (2014) |
Number of employees | 21,600 (2015) |
| Parent | Teva Pharmaceuticals |
| Website | www |
Actavis Generics[1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.
Actavis PLC markets brand products through six franchises in key therapeutic categories including: Aesthetics/Dermatology/Plastic Surgery; Neurosciences/CNS; Eye Care; Women's Health and Urology; GI and Cystic Fibrosis; and Cardiovascular Disease and Infectious Disease.[2] The company's products include Botox,[3] Namenda, Restasis,[4] Linzess, Bystolic,[5] Juvederm,[6] Latisse,[7] Lo Loestrin Fe, Estrace, Teflaro, Dalvance, Ozurdex,[8] Optive,[9] Natrelle,[10] Viibryd, Liletta, Saphris,[11] Enablex, Actonel, Androderm, Gelnique and others.
Actavis PLC also operates the world's third-largest generics business. The company has been ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets. Actavis also develops and out-licenses generic pharmaceutical products outside the US through its Medis third-party business, the world's largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers more than 200 products.[12] Actavis PLC is also developing biosimilars products in oncology and other therapeutic categories, and currently has five biosimilar products in development.[13] Actavis PLC has more than 40 manufacturing and distribution facilities around the world, with a capacity of approximately 40 billion units annually. Actavis Global Operations also included Anda Inc, the fourth-largest US generic pharmaceutical product distributor in the United States.[14]
On June 15, 2015, Actavis plc changed its name to Allergan plc, but the company's U.S. and Canadian generics business will continue to operate under the Actavis name.[15] In July 2015, Allergan PLC announced it would sell its Generics division of the company, including Anda Inc,[16] to Teva Pharmaceuticals for $40.5 billion,[17][18] a transaction proposed for completion by the first quarter of 2016.[19]
- ^ "Analyst cuts Allergan generics sales estimates as Teva deal close nears". FiercePharma. 16 June 2016.
- ^ "Form 10K". Actavis plc.
- ^ "Botox cosmetics". Allergan.
- ^ "Restasis" (PDF). Allergan.
- ^ Barr, Diana (18 February 2014). "Forest Labs to be sold for $25 billion". St. Louis Business Journal.
- ^ "Juvederm". Allergan.
- ^ "Latisse" (PDF). Allergan.
- ^ "Ozurdex". Allergan.
- ^ "Optive". Allergan.
- ^ "Natrelle". Allergan.
- ^ "Form 10K". Actavis plc.
- ^ "Actavis Confirms Favorable Ruling In Generic Pulmicort RESPULES Patent Suit". First Word Pharma.
- ^ John Carroll (18 February 2015). "Can Actavis deliver a promised $6B boost from this pipeline". Fierce Biotech.
- ^ "Actavis Confirms Favorable Ruling In Generic Pulmicort Respules Patent Suit". First Word Pharma.
- ^ Haggerty, Neil (2015-06-15). "Actavis Changes Name to Allergan After Deal for Botox Maker". WSJ. Retrieved 2015-08-07.
- ^ "Teva Completes Acquisition of Actavis Generics". www.businesswire.com. 2016-08-02. Retrieved 2019-03-06.
- ^ "Allergan Accelerates Transformation to Branded Growth Pharma Leader by Divesting Global Generics Business to Teva for $40.5 Billion" (Press release). Allergan. 27 July 2015. Retrieved 4 December 2015.
- ^ Yoel, Minkoff (27 July 2015). "Teva to buy Allergan Generics for $40.5B". Seeking Alpha. Retrieved 4 December 2015.
- ^ O'Donnell, Carl (3 December 2015). "Teva divesting $1 billion in assets to clear Allergan deal". Reuters. Retrieved 4 December 2015 – via Yahoo! Finance.
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search